# Carcinoma, Non-Small-Cell Lung: 60 new trials (2026)

Updated November 19, 2026.

60 new trials for Carcinoma, Non-Small-Cell Lung were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New Carcinoma, Non-Small-Cell Lung clinical trials, last 30 days: 60 rows for $5, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/new/carcinoma-non-small-cell-lung

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 60
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 60, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947134 | A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours | GlaxoSmithKline | Phase 1/2 | Not yet recruiting | Solid Tumours | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947134) |
| November 18, 2026 | NCT07946848 | Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC. | Immuneering Corporation | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946848) |
| November 18, 2026 | NCT07944313 | Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung... | Quanzhou First Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Carcinoma of Lung | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944313) |
| November 17, 2026 | NCT07943325 | Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer | Goethe University | Phase 3 | Not yet recruiting | Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943325) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 16, 2026 | NCT07940257 | Study of Furmonertinib as Follow-Up Treatment After Surgery for Early-Stage EGFR-Positive Lung Cancer: Real-World Observation | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Observational | Active not recruiting | NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Early Stage Lung Non-Small Cell Carcinoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940257) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| November 16, 2026 | NCT07938463 | Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC | Dana-Farber Cancer Institute | Phase 1 | Not yet recruiting | ALK Positive Non-small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938463) |
| November 16, 2026 | NCT07938385 | Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA) | Royal Marsden NHS Foundation Trust | Observational | Recruiting | Impact of the Immune Cell Repertoire on the Therapeutic Index of Radiotherapy, The Need for Serum Markers of... | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938385) |
| November 13, 2026 | NCT07936578 | Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Guizhou Medical University | Phase 2 | Not yet recruiting | Concurrent Chemoradiotherapy, Immunotherapy, Lung Cancer (NSCLC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936578) |
| November 13, 2026 | NCT07936422 | A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients | Centre Leon Berard | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer, Pan-rare Tumor With no T-DXd Approvals, Pan-frequent... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936422) |
| November 13, 2026 | NCT07934966 | Pulmonary Ligament Division vs Preservation in Upper Lobectomy | Ain Shams University | Not applicable | Completed | Lobectomy, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Volume | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934966) |
| November 12, 2026 | NCT07933055 | Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan... | Txinno Bioscience Inc. | Phase 1/2 | Recruiting | NSCLC (Non-small Cell Lung Cancer) | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933055) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 9, 2026 | NCT07926308 | Real-world Outcome of Zongertinib in Japan (J-HERZ) | Boehringer Ingelheim | Observational | Not yet recruiting | Non-small Cell Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926308) |
| November 6, 2026 | NCT07922135 | Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunotherapy in Patients With Unresectable... | Trans Tasman Radiation Oncology Group | Not applicable | Not yet recruiting | Stage III NSCLC | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922135) |
| November 6, 2026 | NCT07921888 | Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA | Sponsor not shown (see the record) | Observational | Recruiting | Non-Small Cell Lung Cancer, Minimal Residual Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921888) |
| November 6, 2026 | NCT07920822 | Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Phase 1 | Enrolling by invitation | Soft Tissue Sarcoma, Non-small Cell Lung Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920822) |
| November 5, 2026 | NCT07919691 | Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy | Ruijin Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919691) |
| November 5, 2026 | NCT07917767 | A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of... | Tang-Du Hospital | Phase 2 | Not yet recruiting | NSCLC Stage IIIA/B, NSCLC Stage II | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917767) |
| November 4, 2026 | NCT07916129 | Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for... | Tianjin Medical University Cancer Institute and Hospital | Not applicable | Enrolling by invitation | Non-Small Cell Carcinoma of Lung | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916129) |
| November 4, 2026 | NCT07914972 | Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients | AstraZeneca | Observational | Not yet recruiting | Non-small Cell Lung Cancer, NSCLC, Stage I-II Unresected NSCLC | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914972) |
| November 3, 2026 | NCT07912593 | A KRAS Inhibitor in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer... | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912593) |
| November 3, 2026 | NCT07912268 | Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912268) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 13 |
| Phase 1/2 | 8 |
| Phase 2 | 13 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |
| Not applicable | 7 |
| Observational | 12 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Immuneering Corporation | 1 |
| Quanzhou First Hospital | 1 |
| Goethe University | 1 |
| SystImmune Inc. | 1 |
| The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Dana-Farber Cancer Institute | 1 |
| Royal Marsden NHS Foundation Trust | 1 |
| Guizhou Medical University | 1 |
| Centre Leon Berard | 1 |
| Ain Shams University | 1 |
| Txinno Bioscience Inc. | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| Trans Tasman Radiation Oncology Group | 1 |
| Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | 1 |
| Tang-Du Hospital | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Ensem Therapeutics | 1 |
| [Jiangsu Simcere Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-simcere-pharmaceutical-co-ltd) | 1 |
| Cho Ray Hospital | 1 |
| Samsung Medical Center | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fabric wholesalers in the United States](https://specstream.ai/data/businesses/fabric-wholesalers/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Diagnostic imaging centers in the United States](https://specstream.ai/data/businesses/diagnostic-imaging-centers/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
- [Chemical plants in the United States](https://specstream.ai/data/businesses/chemical-plants/united-states)
- [Optometrists in the United States](https://specstream.ai/data/businesses/optometrists/united-states)
